Last reviewed · How we verify
Xanomeline and Trospium Chloride
Xanomeline and Trospium Chloride is a Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist Small molecule drug developed by Collaborative Neuroscience Research, LLC. It is currently FDA-approved for Psychosis in Alzheimer's disease.
Xanomeline is a muscarinic M1/M4 receptor agonist combined with trospium chloride, an anticholinergic agent, to enhance cognitive function while mitigating peripheral cholinergic side effects.
Xanomeline is a muscarinic M1/M4 receptor agonist combined with trospium chloride, an anticholinergic agent, to enhance cognitive function while mitigating peripheral cholinergic side effects. Used for Psychosis in Alzheimer's disease.
At a glance
| Generic name | Xanomeline and Trospium Chloride |
|---|---|
| Sponsor | Collaborative Neuroscience Research, LLC |
| Drug class | Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist |
| Target | Muscarinic acetylcholine receptors M1 and M4 (xanomeline); muscarinic receptors peripherally (trospium chloride antagonism) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Xanomeline selectively activates M1 and M4 muscarinic acetylcholine receptors in the brain to improve cognition and reduce psychotic symptoms. Trospium chloride, a peripheral anticholinergic antagonist, blocks unwanted muscarinic effects in the periphery (such as gastrointestinal and urinary effects) without crossing the blood-brain barrier, thereby improving tolerability while preserving central benefits.
Approved indications
- Psychosis in Alzheimer's disease
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Dizziness
- Headache
Key clinical trials
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) (PHASE3)
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) (PHASE3)
- Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) (PHASE3)
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) (PHASE3)
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (PHASE3)
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xanomeline and Trospium Chloride CI brief — competitive landscape report
- Xanomeline and Trospium Chloride updates RSS · CI watch RSS
- Collaborative Neuroscience Research, LLC portfolio CI
Frequently asked questions about Xanomeline and Trospium Chloride
What is Xanomeline and Trospium Chloride?
How does Xanomeline and Trospium Chloride work?
What is Xanomeline and Trospium Chloride used for?
Who makes Xanomeline and Trospium Chloride?
What drug class is Xanomeline and Trospium Chloride in?
What development phase is Xanomeline and Trospium Chloride in?
What are the side effects of Xanomeline and Trospium Chloride?
What does Xanomeline and Trospium Chloride target?
Related
- Drug class: All Muscarinic M1/M4 receptor agonist with peripheral anticholinergic antagonist drugs
- Target: All drugs targeting Muscarinic acetylcholine receptors M1 and M4 (xanomeline); muscarinic receptors peripherally (trospium chloride antagonism)
- Manufacturer: Collaborative Neuroscience Research, LLC — full pipeline
- Therapeutic area: All drugs in Psychiatry / Neurology
- Indication: Drugs for Psychosis in Alzheimer's disease
- Compare: Xanomeline and Trospium Chloride vs similar drugs
- Pricing: Xanomeline and Trospium Chloride cost, discount & access